Natural History Study of SCID Disorders

Related Clinical Trial
cliniMACs HUD for T Cell Depletion Cord Blood Stem Cell Transplantation Study (COBLT) Long Term Follow Up Of Patients Who Have Received Gene Therapy Or Gene Marked Products Lentiviral Gene Therapy for Adenosine Deaminase (ADA) Deficiency Genetic Basis of Immunodeficiency IMM 0212: Busulfan With Fludarabine and Antithymocyte Globulin as Preparative Therapy for Hematopoietic Stem Cell Transplant for the Treatment of Severe Congenital T-Cell Immunodeficiency Sirolimus Prophylaxis for aGVHD in TME SCID Study Through Imaging of Visceral Lymphoid Organs in Patients With SCID Who Have Recieved Bone Marrow Allograft Influences on Female Adolescents’ Decisions Regarding Testing for Carrier Status of XSCID Total-Body Irradiation Followed By Cyclosporine and Mycophenolate Mofetil in Treating Patients With Severe Combined Immunodeficiency Undergoing Donor Bone Marrow Transplant EZN-2279 in Patients With ADA-SCID AMG191 Conditioning/CD34+CD90 Stem Cell Transplant Study for SCID Patients Gene Therapy for X-linked Severe Combined Immunodeficiency (SCID-X1) Newborn Screening for Severe Combined Immunodeficiency (SCID) in a High-Risk Population Gene Transfer for Severe Combined Immunodeficiency, X-linked (SCID-X1) Using a Self-inactivating (SIN) Gammaretroviral Vector Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning Allogeneic SCT Of Pts With SCID And Other Primary Immunodeficiency Disorders Stem Cell Gene Therapy to Treat X-Linked Severe Combined Immunodeficiency (XSCID) Patients Treated for SCID (1968-Present) Clinical Characteristics and Genetic Profiles of Severe Combined Immunodeficiency in China Gene Therapy for ADA-SCID MND-ADA Transduction of CD34+ Cells From Children With ADA-SCID Transplantation of Hematopoietic Cells in Children With Severe Combined Immunodeficiency Syndrome Hematopoietic Stem Cell Transplantation (HSCT) for Children With SCID Utilizing Alemtuzumab, Plerixafor & Filgrastim Natural History Study of SCID Disorders Gene Transfer Therapy for Severe Combined Immunodeficieny Disease (SCID) Due to Adenosine Deaminase (ADA) Deficiency: A Natural History Study Safety and Early Efficacy Study of TBX-1400 in Patients With Severe Combined Immunodeficiency SCID Bu/Flu/ATG Study With T Cell Depletion Generalized Neonatal Screening of Severe Combined Immunodeficiencies Neonatal Screening of Severe Combined Immunodeficiencies Gene Therapy for X-linked Severe Combined Immunodeficiency An Observational LTFU Study for Patients Previously Treated With Autologous ex Vivo Gene Therapy for ADA-SCID Haplocompatible Transplant Using TCRα/β Depletion Followed by CD45RA-Depleted Donor Lymphocyte Infusions for Severe Combined Immunodeficiency (SCID) Registry Study of Revcovi Treatment in Patients With ADA-SCID Multi-center Clinical Study of Cord Blood Stem Cell Transplantation for SCID

Brief Title

Natural History Study of SCID Disorders

Official Title

A Prospective Natural History Study of Diagnosis, Treatment and Outcomes of Children With SCID Disorders (RDCRN PIDTC-6901)

Brief Summary

      This study is a prospective evaluation of children with Severe Combined Immune Deficiency
      (SCID) who are treated under a variety of protocols used by participating institutions. In
      order to determine the patient, recipient and transplant-related variables that are most
      important in determining outcome, study investigators will uniformly collect pre-, post- and
      peri-transplant (or other treatment) information on all children enrolled into this study.

      Children will be divided into three strata:

        -  Stratum A: Typical SCID with virtual absence of autologous T cells and poor T cell
           function

        -  Stratum B: Atypical SCID (leaky SCID, Omenn syndrome and reticular dysgenesis with
           limited T cell diversity or number and reduced function), and

        -  Stratum C: ADA deficient SCID and XSCID patients receiving alternative therapy including
           PEG-ADA ERT or gene therapy.

      Each Group/Cohort Stratum will be analyzed separately.
    

Detailed Description

      This study follows participants with SCID prospectively, meaning the study enrolls
      participants where there is a plan to receive a blood and marrow transplant, enzyme therapy,
      or gene therapy in the future. Participants are then followed according to a schedule set out
      by the study protocol after the procedure. There are no experimental therapies on this study.

      The goal of this study is to learn more about: (1) outcomes from the treatment of SCID in the
      modern era of medicine (2) what factors lead to the best long-term outcomes, such as best
      donor, conditioning regimen, timing of transplant, etc., and (3) what impact newborn
      screening and the early diagnosis of SCID has had on the long-term outcomes following BMT or
      gene therapy. Information is also being gathered on how and when the immune system recovers
      after bone marrow transplant (BMT), quality of life for long-term survivors, and about
      whether children develop normally after treatment.

      This natural history study is the largest coordinated prospective study of participants with
      SCID ever performed. Information that investigators will learn, both now and in the future,
      will help doctors and other health professionals to better treat children with SCID.
    


Study Type

Observational


Primary Outcome

Overall Survival (OS) at Month 6 Post HCT

Secondary Outcome

 T Cell Reconstitution by Stratum-Month 6, Year 2, Year 5 and Year 8 Post-SCID Treatment

Condition

Severe Combined Immunodeficiency (SCID)


Study Arms / Comparison Groups

 Stratum A: Typical SCID +HCT
Description:  Stratum A: Typical Severe Combined Immunodeficiency (SCID) treated with HCT therapy.
Participants with typical (formerly referred to as classic) SCID + allogeneic hematopoietic stem cell transplantation (HCT) therapy according to standard of care, per local protocol.

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information



Estimated Enrollment

690

Start Date

September 2, 2010

Completion Date

September 2028

Primary Completion Date

September 2028

Eligibility Criteria

        Inclusion Criteria:

        Stratum A: Typical SCID (formerly referred to as Classic SCID)- -Subjects who meet the
        following inclusion criteria and the intention is to treat with allogeneic hematopoietic
        cell transplant (HCT) are eligible for enrollment into Stratum A (Typical SCID) of the
        study:

          -  Absence or very low number of T cells (CD3 T cells <300/microliter) AND

          -  No or very low T cell function (<10% of lower limit of normal) as measured by response
             to phytohemagglutinin (PHA) OR

          -  T cells of maternal origin present.

        Stratum B: Leaky SCID, Omenn Syndrome, Reticular Dysgenesis-

        -Subjects who meet the following criteria and the intention is to treat with HCT are
        eligible for enrollment into Stratum B:

        Leaky SCID:

          -  Maternal lymphocytes tested for and not detected AND

          -  Either one or both of the following (a,b) :

               -  a.) <50% of lower limit of normal T cell function as measured by response to PHA,
                  OR response to anti-CD3/CD28 antibody

               -  b.) Absent or <30% of lower limit of normal proliferative responses to candida
                  and tetanus toxoid antigens

          -  AND at least two of the following (a through e):

               -  a.) Reduced number of CD3 T cells

                    -  age ≤2 years: <1500/microliter

                    -  age >2 years and ≤4 years: <800/microliter

                    -  age >4 years: <600/microliter

               -  b.) ≥80% of CD3+ or CD4+ T cells that are CD45RO+

                    -  AND/OR >80% of CD3+ or CD4+ T cells are CD62L negative

                    -  AND/OR >50% of CD3+ or CD4+T cells express HLA-DR (at <4 years of age)

                    -  AND/OR are oligoclonal T cells

               -  c.) Hypomorphic mutation in IL2RG in a male, or homozygous hypomorphic mutation
                  or compound heterozygosity with ≥1 hypomorphic mutation in an autosomal
                  SCID-causing gene

               -  d.) Low T Cell Receptor Excision Circles (TRECs) and/or the percentage of
                  CD4+/45RA+/CD31+ or CD4+/45RA+/CD62L+ cells is below the lower limit of normal.

               -  e.) Functional testing in vitro supporting impaired, but not absent, activity of
                  the mutant protein, AND

          -  Does not meet criteria for Omenn Syndrome.

        Omenn Syndrome:

          -  Generalized skin rash

          -  Maternal lymphocytes tested for and not detected;

             --Note: If maternal engraftment was not assessed and ruled out, the subject is not
             eligible as Omenn Syndrome.

          -  ≥80% of CD3+ or CD4+ T cells are CD45RO+ AND/OR

               -  80% of CD3+ or CD4+T cells are CD62L negative AND/OR

               -  50% of CD3+ or CD4+ T cells express HLA-DR (at <2 years of age);

          -  Absent or low (< 30% lower limit of normal) T cell proliferation response to antigens
             (Candida, tetanus) to which the subject has been exposed

        NOTE: If proliferation to antigen was not performed, but at least 4 of the following 9
        supportive criteria, at least one of which must be among those marked with an asterisk (*)
        below are present, the subject is eligible as Omenn Syndrome:

          -  Hepatomegaly

          -  Splenomegaly

          -  Lymphadenopathy

          -  Elevated IgE

          -  Elevated absolute eosinophil count

          -  *Oligoclonal T cells measured by CDR3 length or flow cytometry

          -  *Proliferation to PHA is reduced <50% of lower limit of normal or SI <30

          -  *Hypomorphic mutation in a SCID causing gene

          -  Low TRECS and/or the percentage of CD4+/45RA+/CD31+ or CD4+/45RA+/CD62L+ cells is
             below the lower limit of normal.

        Reticular Dysgenesis:

          -  Absence or very low number of T cells (CD3 <300/µL

          -  No or very low (<10% lower limit of normal) T cell response to PHA

          -  Severe neutropenia (absolute neutrophil count < 200 /µL) AND

          -  ≥2 of the following (a,b,c):

               -  a.) Sensori-neural deafness

               -  b.) Deficiency of marrow granulopoiesis on bone marrow examination

               -  c.) A pathogenic mutation in the adenylate kinase 2 (AK2) gene identified.

        Stratum C:

        Subjects who meet the following criteria and the intention is to treat with therapy other
        than allogeneic HCT, primarily PEG-ADA ERT or gene therapy with autologous modified (gene
        transduced) cells, are eligible for enrollment into

        Stratum C:

          -  ADA Deficient SCID with intention to treat with PEG-ADA ERT

          -  ADA Deficient SCID with intention to treat with gene therapy

          -  X-linked SCID with intention to treat with gene therapy

          -  Any SCID patient previously treated with a thymus transplant (includes intention to
             treat with HCT, as well as PEG-ADA ERT or gene therapy)

          -  Any SCID patient who received therapy for SCID deemed "non-standard" or
             "investigational", including in utero procedures.

        Exclusion Criteria:

        -Subjects who meet any of the following exclusion criteria are disqualified from enrollment
        in Strata A, B, or C of the study:

          -  Presence of an Human Immunodeficiency Virus (HIV) infection (by PCR) or other cause of
             secondary immunodeficiency

          -  Presence of DiGeorge syndrome

          -  MHC Class I and MHC Class II antigen deficiency, and

          -  Metabolic conditions that imitate SCID or related disorders such as folate transporter
             deficiency, severe zinc deficiency or transcobalamin deficiency.
      

Gender

All

Ages

N/A - N/A

Accepts Healthy Volunteers

No

Contacts

Christopher C. Dvorak, MD, , 

Location Countries

Canada

Location Countries

Canada

Administrative Informations


NCT ID

NCT01186913

Organization ID

DAIT RDCRN PIDTC-6901


Responsible Party

Sponsor

Study Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

Collaborators

 Primary Immune Deficiency Treatment Consortium (PIDTC)

Study Sponsor

Christopher C. Dvorak, MD, Principal Investigator, UCSF Children's Hospital


Verification Date

September 2019